Jiankun Lyu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2615396/publications.pdf

Version: 2024-02-01

		759233	1058476
13	5,105	12	14
papers	citations	h-index	g-index

17	17	17	11413
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 2020, 583, 459-468.	27.8	3,542
2	Ultra-large library docking for discovering new chemotypes. Nature, 2019, 566, 224-229.	27.8	595
3	Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor. Cell, 2020, 182, 1574-1588.e19.	28.9	270
4	A practical guide to large-scale docking. Nature Protocols, 2021, 16, 4799-4832.	12.0	206
5	Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. Science, 2021, 373, 541-547.	12.6	148
6	Structures of the Ïƒ2 receptor enable docking for bioactive ligand discovery. Nature, 2021, 600, 759-764.	27.8	113
7	Property-Unmatched Decoys in Docking Benchmarks. Journal of Chemical Information and Modeling, 2021, 61, 699-714.	5.4	48
8	Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget, 2016, 7, 64967-64976.	1.8	42
9	Selectivity Challenges in Docking Screens for GPCR Targets and Antitargets. Journal of Medicinal Chemistry, 2018, 61, 6830-6845.	6.4	31
10	Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants. Journal of Medicinal Chemistry, 2016, 59, 6187-6200.	6.4	28
11	Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. Journal of Medicinal Chemistry, 2018, 61, 5609-5622.	6.4	27
12	Antiproliferative and apoptosis-inducing activities of novel naphthalimideâ€“cyclam conjugates through dual topoisomerase (topo) I/II inhibition. Bioorganic and Medicinal Chemistry, 2015, 23, 5672-5680.	3.0	23
13	Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors. Scientific Reports, 2017, 7, 3830.	3.3	11